Back | Next |
home / stock / nrsn / nrsn message board
Subject | By | Source | When |
---|---|---|---|
$NRSN short squeeze signal | 420man | investorshub | 05/27/2023 11:10:35 AM |
$NRSN MomentumIts now | crudeoil24 | investorshub | 05/26/2023 11:15:18 AM |
$NRSN MomentumIts trading last up | subslover | investorshub | 05/26/2023 6:09:03 AM |
Price now | THEMASTERS_SON | investorshub | 05/25/2023 8:35:35 PM |
THANK YOU!!! | subslover | investorshub | 02/08/2023 2:43:49 PM |
Some news on watch again | tw0122 | investorshub | 02/08/2023 2:21:27 PM |
znewcar1: $NRSN 76% v81,4M c2.22 f11,6M h2.91 ML1.08 lod2.03 | znewcar1 | investorshangout | 01/19/2023 9:11:10 PM |
Probaby time for another 424B3 shelf placement! | crudeoil24 | investorshub | 01/19/2023 3:06:36 PM |
NeuroSense Therapeutics Sees Positive Trial Results for TDP-43 | crudeoil24 | investorshub | 01/19/2023 3:04:05 PM |
Boom | harry crumb | investorshub | 01/19/2023 2:28:35 PM |
Im out. Nice 60%! TY | lowercaseBACON | investorshub | 06/30/2022 1:46:06 PM |
Thanks so much, buddy. Wishing you all the | subslover | investorshub | 06/30/2022 1:06:10 PM |
No worries. Good luck with all your trades. $NRSN | frankyahoo | investorshub | 06/30/2022 1:01:38 PM |
Sorry, bro, many others will pop. Biotechs heating | subslover | investorshub | 06/30/2022 12:58:31 PM |
Saw this. Unfortunately, I clipped it yesterday. Left | frankyahoo | investorshub | 06/30/2022 12:53:22 PM |
Good morning Franky buddy. It's payday baby! | subslover | investorshub | 06/30/2022 12:51:14 PM |
$NRSN is running hot on the RSI for | lowercaseBACON | investorshub | 06/29/2022 7:55:46 PM |
Ty. Good to see you too. Let's make bank | frankyahoo | investorshub | 06/29/2022 1:16:15 PM |
Hi franky, great to see you! Yea this | subslover | investorshub | 06/29/2022 12:59:27 PM |
Wow! Finally moving. I mean ALS...Come on man! | frankyahoo | investorshub | 06/29/2022 12:57:13 PM |
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...